About the Company
Avalon GloboCare Corp. is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
Sector
Health Care and Social Assistance
Industry
General Medical and Surgical Hospitals
Employees
7
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AVCO News
Diagnostic Industry Revelations: Comprehensive Analysis of Global Distribution Deals from 2016 to 2024 Unveiled
Dublin, March 05, 2024 (GLOBE NEWSWIRE) -- The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to ResearchAndMarkets.com's offering. A newly compiled research publication ...
We don't have any news on Avalon GloboCare Corp at the moment.
Loading the latest forecasts...